Neurotech International Limited (ASX:NTI)
0.0140
+0.0010 (7.69%)
Mar 4, 2026, 4:10 PM AEST
Neurotech International Revenue
Neurotech International had revenue of 2.33M AUD in the half year ending June 30, 2025. This brings the company's revenue in the last twelve months to 7.07M, up 8,687.82% year-over-year. In the fiscal year ending June 30, 2025, Neurotech International had annual revenue of 2.44M, down -23.07%.
Revenue (ttm)
7.07M
Revenue Growth
+8,687.82%
P/S Ratio
2.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.44M | -732.95K | -23.07% |
| Jun 30, 2024 | 3.18M | 1.98M | 166.00% |
| Jun 30, 2023 | 1.19M | 586.87K | 96.59% |
| Jun 30, 2022 | 607.62K | 401.25K | 194.44% |
| Jun 30, 2021 | 206.37K | 126.03K | 156.86% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| Tissue Repair | 3.26M |
| Noxopharm | 2.68M |
| Avecho Biotechnology | 1.24M |
| Argenica Therapeutics | 1.01M |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| NeuroScientific Biopharmaceuticals | 341.16K |